CEO Q&A with Neil Crabb at Frontier IP Group Plc (LON:FIPP)

Frontier IP Group Plc (LON:FIPP) Chief Executive Officer Neil Crabb caught up with DirectorsTalk for an exclusive interview to discuss their 24% stake in Cambridge Materials Testing Solutions.

 

Q1: You’ve announced that you’ve taken a 24% stake in a new spin-out, Cambridge Material Testing Solutions. Can you tell us what the company does?

A1: So centrally, it’s focussed on the problem in a range of industries, companies need to understand the materials they’re using because that’s a critical point of successful failure. So, if you think about nuclear, oil and gas, the aerospace sectors, all of them are dependent on the performance of the materials that they use.

Cambridge Materials Testing Solutions, which is the new company, is developing technology to help them to do this in a more rapid, cost-effective and accurate manner than other systems. It does that through a fleet of software called SEMPID which essentially takes the data it generates from test equipment and converts that into information that engineers can use to assess the strength and remaining working life of metal components.

The company is also developing new hardware to allow essentially in-situ testing by creating an indent and seeing how the material responds to that so that potentially the component doesn’t have to be removed from where it’s being used in order to predict whether it’s going to fail or not. That’s very attractive from an operating point of view for the company that’s using the critical component.

 

Q2: So, who’s behind the technology in Cambridge Materials Testing?

A2: The principal academic is Dr James Dean, he’s obviously an expert in both the mechanics and deformation of materials, University of Cambridge PhD. Interestingly, he has previously worked in industries as well for a group called Frazer Nash Consultancy who are leading consultants in this area and then also set up his own consultancy Double Precision Consultancy which again is servicing the needs of industry players. So, whilst he’s got a very strong academic background, he’s also got a good understanding of the industrial requirements and indeed has worked in both the nuclear and aerospace industries supporting clients in that area.

 

Q3: Where does this fit into your wider IP picture?

A3: So, materials testing and particles are all important parts, I would say, across our portfolio, it’s an area of particular focus and expertise. So, if you looked at Frontier IP Group’s portfolio, Tarsis Technology, Nandi Proteins, Alusid, Porexpert are all actively involved in some element of materials or particle formation and all are currently engaged with industrial or commercial partners as well which we see as really important.

In terms of the target sectors, Cambridge Materials Testing itself probably fits closest with Porexpert which provides software and consultancy services to help customers understand how porous materials behave and how gases and liquids flow through them so they’re most notable customer would be EDF for example.

What we’re now looking for is, by gaining early industry validation, we know that we’re technically involved in meeting real world needs and demands and can be scaled up and obviously that makes them much more attractive to investors as well.

 

Q4: What else is happening with Frontier IP Group’s portfolio?

A4: We recently announced that Palintest which is a subsidiary of the FTSE100 company Halma has commercially launched a test kit for bathing water and that’s come out of a company called Molendotech in our portfolio.

Alusid, which recycles waste porcelain and glass to create really high quality building materials, has won a number of industry awards and is gaining strong traction with a range of industry customers, people like Nando’s and such like. We’ve said already that that’s currently raising money and that’s going well.

Otherwise, watch this space. There’s an awful lot going on, so we would expect to be updating the market on further progress within the portfolio.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.